Connection

Co-Authors

This is a "connection" page, showing publications co-authored by DIHUA YU and MIEN-CHIE HUNG.
Connection Strength

4.703
  1. Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. Int J Biol Sci. 2023; 19(10):2957-2973.
    View in: PubMed
    Score: 0.235
  2. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.225
  3. Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Res. 2022 06 06; 82(11):2185-2195.
    View in: PubMed
    Score: 0.220
  4. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem. 2022 04; 298(4):101817.
    View in: PubMed
    Score: 0.216
  5. An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protoc. 2022 03 18; 3(1):101198.
    View in: PubMed
    Score: 0.215
  6. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
    View in: PubMed
    Score: 0.204
  7. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 2021 04 15; 131(8).
    View in: PubMed
    Score: 0.203
  8. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021 02 05; 12(1):832.
    View in: PubMed
    Score: 0.200
  9. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000 Dec 11; 19(53):6115-21.
    View in: PubMed
    Score: 0.198
  10. The impact of PD-L1?N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020 Jul 03; 27(1):77.
    View in: PubMed
    Score: 0.192
  11. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med. 2020 05 27; 12(545).
    View in: PubMed
    Score: 0.191
  12. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998 Apr 23; 16(16):2087-94.
    View in: PubMed
    Score: 0.165
  13. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
    View in: PubMed
    Score: 0.149
  14. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996 Sep 19; 13(6):1359-65.
    View in: PubMed
    Score: 0.148
  15. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.147
  16. Upregulation of lactate dehydrogenase a by 14-3-3? leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. 2016 Jun 07; 7(23):35270-83.
    View in: PubMed
    Score: 0.145
  17. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. Am J Cancer Res. 2015; 5(12):3624-34.
    View in: PubMed
    Score: 0.139
  18. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995 Oct 05; 11(7):1383-8.
    View in: PubMed
    Score: 0.138
  19. 14-3-3? turns TGF-?'s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015 Feb 09; 27(2):177-92.
    View in: PubMed
    Score: 0.132
  20. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014 Jul 29; 7(336):ra71.
    View in: PubMed
    Score: 0.127
  21. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res. 2014; 6(4):361-76.
    View in: PubMed
    Score: 0.127
  22. Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35.
    View in: PubMed
    Score: 0.127
  23. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One. 2013; 8(9):e73406.
    View in: PubMed
    Score: 0.120
  24. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011 Mar; 13(3):317-23.
    View in: PubMed
    Score: 0.100
  25. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res. 2010 Oct 01; 70(19):7684-9.
    View in: PubMed
    Score: 0.097
  26. Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene. 2009 Jul 02; 28(26):2436-45.
    View in: PubMed
    Score: 0.089
  27. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab. 2023 08 08; 35(8):1457-1473.e13.
    View in: PubMed
    Score: 0.059
  28. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv. 2023 02 03; 9(5):eadd6995.
    View in: PubMed
    Score: 0.057
  29. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022 11 02; 14(669):eabo1981.
    View in: PubMed
    Score: 0.056
  30. Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis. Oncogene. 2001 May 03; 20(20):2537-43.
    View in: PubMed
    Score: 0.051
  31. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851.
    View in: PubMed
    Score: 0.045
  32. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.
    View in: PubMed
    Score: 0.040
  33. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene. 1997 Apr 24; 14(16):1965-71.
    View in: PubMed
    Score: 0.039
  34. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2015 Mar; 9(3):586-600.
    View in: PubMed
    Score: 0.032
  35. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012 May 25; 149(5):1098-111.
    View in: PubMed
    Score: 0.027
  36. Localizing the EGF receptor. Nat Cell Biol. 2002 Feb; 4(2):E22; author reply E22-3.
    View in: PubMed
    Score: 0.027
  37. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006 May; 3(5):269-80.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.